The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
From charcot to lou gehrig: deciphering selective motor neuron death in als
Cleveland, D. W., & Rothstein, J. D. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097565 · Cited by 1,389
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., et al. (1997) · Neuron · doi:10.1016/s0896-6273(00)80272-x · Cited by 1,341
Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Dorpe, J. V., Hellings, P., Gorselink, M., Heymans, S., et al. (2001) · Nature Genetics · doi:10.1038/88842 · Cited by 1,007
Self-citationRosen, D. (1993) · Nature · doi:10.1038/364362c0 · Cited by 922
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 1×
“When injecting a similar amount of a rabies-G pseudotyped EIAV vector expressing glial-cell-line-derived neurotrophic factor (GDNF)—which has been previously reported to delay motor neuron loss in ALS mic”
MethodLambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S. L., Wyns, S., Thijs, V., Andersson, J., van Marion, I., et al. (2003) · Nature Genetics · doi:10.1038/ng1211 · Cited by 860
Self-citationFukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., & Semenza, G. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203781200 · Cited by 821
Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia
Jin, K. L., Mao, X. O., & Greenberg, D. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10242 · Cited by 684
Cited by
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
“Recent work in rodent models of SMA and ALS have demonstrated the potential of gene delivery using viruses that undergo retrograde transport after intramuscular injection, and this approach is currently being explored for clinical trial”
BackgroundALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors
Boillée, S., Vande Velde, C., & Cleveland, D. W. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.018 · Cited by 1,429
Takahashi, H., & Shibuya, M. (2005) · Clinical Science · doi:10.1042/cs20040370 · Cited by 953
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703
“A neuroprotective role for VEGF is supported by studies demonstrating delayed motor neuron disease onset and progression in mutant SOD1 models with genetic overexpression of VEGF,(34) intracerebroventricular administration of VEGF,(35) or intramuscular delivery of VEGF-expressing lentiviral vectors.(36) In addition to…”
BackgroundApoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
FADEEL, B., & ORRENIUS, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 698
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis
Greenway, M. J., Andersen, P. M., Russ, C., Ennis, S., Cashman, S., Donaghy, C., Patterson, V., Swingler, R., Kieran, D., Prehn, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1742 · Cited by 667
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
Saint-Geniez, M., Maharaj, A. S. R., Walshe, T. E., Tucker, B. A., Sekiyama, E., Kurihara, T., Darland, D. C., Young, M. J., & D'Amore, P. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003554 · Cited by 616
Mitchell, J., & Borasio, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60944-1 · Cited by 561
Energy metabolism in amyotrophic lateral sclerosis
Dupuis, L., Pradat, P.-F., Ludolph, A. C., & Loeffler, J.-P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70224-6 · Cited by 537
Altering the Tropism of Lentiviral Vectors through Pseudotyping
Cronin, J., Zhang, X.-Y., & Reiser, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054546224 · Cited by 536
From angiogenesis to neuropathology
Greenberg, D. A., & Jin, K. (2005) · Nature · doi:10.1038/nature04481 · Cited by 532
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
“The strategy reported here provides an effective method for gene downregulation that may be applicable to multiple neurodegenerative diseases and incorporates 2 central advantages over current viral gene therapy approaches (29–31).”
BackgroundRalph, G. S., Radcliffe, P. A., Day, D. M., Carthy, J. M., Leroux, M. A., Lee, D. C. P., Wong, L.-F., Bilsland, L. G., Greensmith, L., Kingsman, S. M., et al. (2005) · Nature Medicine · doi:10.1038/nm1205 · Cited by 506
Self-citationTransgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS
TURNER, B., & TALBOT, K. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.001 · Cited by 496
Storkebaum, E., Lambrechts, D., Dewerchin, M., Moreno-Murciano, M.-P., Appelmans, S., Oh, H., Van Damme, P., Rutten, B., Man, W. Y., De Mol, M., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1360 · Cited by 494
Self-citationMotor Neuron Diversity in Development and Disease
Kanning, K. C., Kaplan, A., & Henderson, C. E. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135722 · Cited by 478
Raoul, C., Abbas-Terki, T., Bensadoun, J.-C., Guillot, S., Haase, G., Szulc, J., Henderson, C. E., & Aebischer, P. (2005) · Nature Medicine · doi:10.1038/nm1207 · Cited by 464
Role and Therapeutic Potential of VEGF in the Nervous System
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., & Carmeliet, P. (2009) · Physiological Reviews · doi:10.1152/physrev.00031.2008 · Cited by 448
Self-citationZhu, C., Jung, S., Luo, S., Meng, F., Zhu, X., Park, T. G., & Zhong, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.077 · Cited by 440
Stem cell‐based cell therapy in neurological diseases: A review
Kim, S. U., & de Vellis, J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22054 · Cited by 426
The “Dying-Back” Phenomenon of Motor Neurons in ALS
Dadon-Nachum, M., Melamed, E., & Offen, D. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9467-1 · Cited by 412
Amyotrophic Lateral Sclerosis: A Focus on Disease Progression
Calvo, A. C., Manzano, R., Mendonça, D. M. F., Muñoz, M. J., Zaragoza, P., & Osta, R. (2014) · BioMed Research International · doi:10.1155/2014/925101 · Cited by 403
Vascular endothelial growth factor: a neurovascular target in neurological diseases
Lange, C., Storkebaum, E., de Almodóvar, C. R., Dewerchin, M., & Carmeliet, P. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.88 · Cited by 382
Self-citationLost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Neurovascular signalling defects in neurodegeneration
Zacchigna, S., Lambrechts, D., & Carmeliet, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2336 · Cited by 345
Self-citationMoloney, E. B., de Winter, F., & Verhaagen, J. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00252 · Cited by 307
Diverse roles for VEGF-A in the nervous system
Mackenzie, F., & Ruhrberg, C. (2012) · Development · doi:10.1242/dev.072348 · Cited by 294
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Reduced oxidative damage in ALS by high‐dose enteral melatonin treatment
Weishaupt, J. H., Bartels, C., Pölking, E., Dietrich, J., Rohde, G., Poeggeler, B., Mertens, N., Sperling, S., Bohn, M., Hüther, G., et al. (2006) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00377.x · Cited by 282
Genetics of familial amyotrophic lateral sclerosis
Valdmanis, P. N., & Rouleau, G. A. (2008) · Neurology · doi:10.1212/01.wnl.0000296811.19811.db · Cited by 281
Gene therapy: can neural stem cells deliver?
Müller, F.-J., Snyder, E. Y., & Loring, J. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1829 · Cited by 274
FTD and ALS: A Tale of Two Diseases
Ferrari, R., Kapogiannis, D., D. Huey, E., & Momeni, P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563700 · Cited by 272
Zachary, I. (2005) · Neurosignals · doi:10.1159/000088637 · Cited by 266
GDNF Delivery Using Human Neural Progenitor Cells in a Rat Model of ALS
Klein, S. M., Behrstock, S., McHugh, J., Hoffmann, K., Wallace, K., Suzuki, M., Aebischer, P., & Svendsen, C. N. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.509 · Cited by 265
Human Neural Stem Cell Grafts Ameliorate Motor Neuron Disease in SOD-1 Transgenic Rats
Xu, L., Yan, J., Chen, D., Welsh, A. M., Hazel, T., Johe, K., Hatfield, G., & Koliatsos, V. E. (2006) · Transplantation · doi:10.1097/01.tp.0000235532.00920.7a · Cited by 258
Themis, M., Waddington, S. N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., Gregory, L. G., Nivsarkar, M., Themis, M., Holder, M. V., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.358 · Cited by 243
Sun, Y., Jin, K., Childs, J. T., Xie, L., Mao, X. O., & Greenberg, D. A. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2005.10.016 · Cited by 178
VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration
Carmeliet, P., & de Almodovar, C. R. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1283-7 · Cited by 173
Self-citationAmyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Katsouri, L., Lim, Y. M., Blondrath, K., Eleftheriadou, I., Lombardero, L., Birch, A. M., Mirzaei, N., Irvine, E. E., Mazarakis, N. D., & Sastre, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606171113 · Cited by 146
“Azzouz M, et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.”
BackgroundSelf-citationMazzini, L., Gelati, M., Profico, D. C., Sorarù, G., Ferrari, D., Copetti, M., Muzi, G., Ricciolini, C., Carletti, S., Giorgi, C., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0154 · Cited by 128
Raab, S., & Plate, K. H. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0228-3 · Cited by 120
Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis
Cappello, V., & Francolini, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102092 · Cited by 119
“In support of the idea of a cross talk between motor axon terminals and muscle fibers, it was also shown that overexpression of Vascular endothelial growth factor (VEGF) and GDNF restricted to the skeletal muscle of SOD1 G93A significantly delayed the onset of the disease and increased mouse survival [85,86].”
BackgroundMethods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
VEGF is required for dendritogenesis of newly born olfactory bulb interneurons
Licht, T., Eavri, R., Goshen, I., Shlomai, Y., Mizrahi, A., & Keshet, E. (2010) · Development · doi:10.1242/dev.039636 · Cited by 86
Impaired Mitophagy Plays a Role in Denervation of Neuromuscular Junctions in ALS Mice
Rogers, R. S., Tungtur, S., Tanaka, T., Nadeau, L. L., Badawi, Y., Wang, H., Ni, H.-M., Ding, W.-X., & Nishimune, H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00473 · Cited by 83
“Amyotrophic lateral sclerosis (ALS) is a common and fatal motor neuron disease, but the etiology has not been elucidated fully (Bordet et al., 2001; Acsadi et al., 2002; Kaspar et al., 2003; Azzouz et al., 2004; Gould et al., 2006; Sorenson et al., 2008; Howe et al., 2009; Reyes et al., 2010; Jeong et al., 2011).”
BackgroundPGC-1 is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis
Eschbach, J., Schwalenstocker, B., Soyal, S. M., Bayer, H., Wiesner, D., Akimoto, C., Nilsson, A.-C., Birve, A., Meyer, T., Dupuis, L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt202 · Cited by 75
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74
Clinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
Campanari, M.-L., García-Ayllón, M.-S., Ciura, S., Sáez-Valero, J., & Kabashi, E. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00160 · Cited by 69
Petri, S., Calingasan, N. Y., Alsaied, O. A., Wille, E., Kiaei, M., Friedman, J. E., Baranova, O., Chavez, J. C., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04604.x · Cited by 55
“The administration of VEGF via intracerebroventricular delivery or retrogradely transported lentiviral vectors prolongs survival in the ALS transgenic mouse model (Azzouz et al. 2004; Storkebaum et al. 2005).”
BackgroundMohan, R., Tosolini, A. P., & Morris, R. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.045 · Cited by 48
Intramuscular Delivery of Gene Therapy for Targeting the Nervous System
Tosolini, A. P., & Sleigh, J. N. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00129 · Cited by 32
Mouse models of neurodegenerative disease: preclinical imaging and neurovascular component
Albanese, S., Greco, A., Auletta, L., & Mancini, M. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9770-3 · Cited by 16
Metadata
- Authors
- Azzouz, M., Ralph, G. S., Storkebaum, E., Walmsley, L. E., Mitrophanous, K. A., Kingsman, S. M., Carmeliet, P., & Mazarakis, N. D.
- Venue
- Nature
- Published
- 2004-05
- Volume
- 429
- Issue
- 6990
- Pages
- 413-417
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2064640860
- Cited by
- 590
- References
- 29
- FWCI
- 33.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.